论文部分内容阅读
本文报道了69例不适宜手术和放疗的晚期食管癌病人的治疗情况。所有病例均经病理和/或细胞学证实并随机分为二组。治疗组35例用POD(平阳霉素+VCR+DDP+活瘀扶正方治疗一疗程,CR9例(25.7％),PR13例(37.1％),有效率(CR+PR)6.28％(22例)对照组34例单用POD方案化疗一疗程,CR3例(8.8％),PR12例35.3％,有效率(CR+PR)44.1％。 治疗前后合并治疗组中19例进行了血液流变学检查,有17例(89.5％)病人全血粘度下降,其中达CR+PR的11例全部(100％)下降,单用POD对照组受检15例,其中8例(53.3％)病人的全血粘度下降,达CR+PR者6例,其中3例(50％)下降。 结论:中西药物联合治疗食管癌优于单纯化疗组。
This article reports on the treatment of 69 patients with advanced esophageal cancer who are not suitable for surgery and radiotherapy. All cases were confirmed by pathology and/or cytology and randomly divided into two groups. In the treatment group, 35 patients were treated with POD (Pingyangmycin + VCR + DDP + Huoqi Fuzheng) for one course of treatment, CR9 (25.7%), PR13 (37.1%), and effective rate (CR+PR) 6.28% (22 cases) A total of 34 patients received single-use POD regimen for one course of treatment, CR3 (8.8%), PR12 (35.3%), and effective rate (CR+PR) of 44.1%.19 patients in the combined treatment group received hemorheology examination before and after treatment. In 17 patients (89.5%), the whole blood viscosity decreased. All 11 patients with CR+PR decreased (100%). 15 patients with POD alone had 15 patients, and 8 patients (53.3%) had decreased whole blood viscosity. There were 6 patients with CR+PR, 3 of them (50%) decreased.Conclusion: Chinese and Western medicine combined treatment of esophageal cancer is superior to chemotherapy alone.